Metotrexato Accord

Methotrexate, the active ingredient in Metotrexato Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable for intra‑arterial, intramuscular, or intravenous use. It is employed to treat autoimmune disorders and several malignancies in adult and pediatric patients. GNH USA supplies Metotrexato Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: induces remission by inhibiting leukemic cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination chemotherapy. - Breast cancer: used in adjuvant regimens to limit tumor growth.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset often occurring shortly after administration. - Fatigue: persistent tiredness that may affect daily activities. - Elevated liver enzymes: mild hepatic irritation detectable on blood tests. - Mouth sores: ulceration of oral mucosa causing discomfort.

Serious or Rare Side Effects: - Bone marrow suppression: pancytopenia leading to infection or bleeding risk. - Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea. - Severe hepatic injury: fibrosis or cirrhosis with prolonged use.

Methotrexate requires careful monitoring and patient education to minimise risks. - Monitor blood counts: regular CBC testing is required to detect marrow suppression. - Assess liver function: periodic liver enzyme tests help identify hepatotoxicity early. - Evaluate renal function: dose adjustments may be needed for impaired clearance. - Avoid pregnancy: effective contraception is mandatory for both sexes during treatment and for a defined period after cessation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase methotrexate toxicity by reducing renal clearance. - Proton pump inhibitors (PPIs): may elevate serum methotrexate levels, heightening adverse effects.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: can potentiate bone marrow suppression. - Azathioprine or other immunosuppressants: may enhance immunosuppressive effects. - Live vaccines: risk of infection due to compromised immunity.